EPISODE · May 4, 2026 · 1 MIN
UCB's $2.2B Candid Buyout: Game-Changer for Immunology
from The Daily News Now! Business
UCBs $2.2 billion acquisition of Candid Therapeutics brings a promising bispecific antibody, cizutamig, to their pipeline, targeting autoimmune and inflammatory diseases. The deal, expected to close in Q2 or Q3, includes an additional $200 million if milestones are met. UCBs CEO hails it as a game-changer, while Candids head praises UCBs immunology expertise. The acquisition aligns with UCBs strategy to strengthen their next-gen immunology portfolio. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6a1d0e80f312d590
NOW PLAYING
UCB's $2.2B Candid Buyout: Game-Changer for Immunology
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m